| Document |
Document Title |
|
WO/2005/120439A1 |
The invention relates to a photopolymerisable dental composition, by means of radiation at a wavelength greater than 390 nm, comprising a photosensitizer (E) which is a salt of a thioxanthone substituted by at least one group (G), compri...
|
|
WO/2005/108338A1 |
The present invention is directed to novel compounds according to formulae (I) wherein R1, R2, R3 and R4 are as defined herein. The invention also discloses methods of preparation, pharmaceutical compositions, and methods of disease trea...
|
|
WO/2005/105770A2 |
The present invention relates in part to compounds of formulas I and III: and pharmaceutically-acceptable salts and prodrugs thereof. These compounds can be useful for treating diseases such as inflammatory and immune diseases. The prese...
|
|
WO/2005/100311A1 |
The present invention provides compounds of formula (I), wherein the constituent members are defined in the claims, pharmaceutical compositions thereof and methods for treating excessive sleepiness associated with narcolepsy, obstructive...
|
|
WO/2005/095326A2 |
Disclosed are compounds of the formula: where variables Q, Z, X, R15, R2, R3, and Rc are defined herein. Compounds disclosed herein are inhibitors of the beta-secretase enzyme and are therefore useful in the treatment of Alzheimer’s di...
|
|
WO/2005/092840A1 |
The invention relates to compounds of formula (1) and to processes for the preparation of, intermediates used in the preparation of, compositions containing and the uses of, such derivatives. The compounds according to the present invent...
|
|
WO/2005/087710A1 |
A compound represented by the formula (1) (wherein the symbols are the same as defined in the description), a salt thereof, and a prodrug thereof. They unexpectedly have excellent GPR40 receptor agonistic activity and are excellent in pr...
|
|
WO/2005/087751A2 |
The invention relates to novel compounds and also to methods of treating at least one disease, disorder, or condition associated with amyloidosis using such compounds. Amyloidosis refers to a collection of diseases, disorders, and condit...
|
|
WO/2005/087215A1 |
The invention relates to acetyl 2-hydroxy-1,3-diaminospirocyclohexanes and derivatives thereof that are useful in treating at least one disease, disorder, and condition associated with amyloidosis. Amyloidosis refers to a collection of d...
|
|
WO/2005/080322A1 |
A novel fluorene characterized by having a fluorene skeleton to which a functional group such as a guanidino group is attached via a carbonyl group, or its salt. This compound has such an advantage as showing a high affinity particularly...
|
|
WO/2005/073204A1 |
The present invention relates to a selective estrogen receptor modulator of formula I or Ia: (I) (Ia); or a pharmaceutical acid addition salt thereof; useful for treating vasomotor symptoms, in particular hot flashes, night sweats and ot...
|
|
WO/2005/073206A1 |
The present invention relates to a selective estrogen receptor modulator of formula I: or a pharmaceutical acid addition salt thereof; useful, e.g., for treating endometriosis and uterine leiomyoma.
|
|
WO/2005/068415A1 |
Disclosed is a phenylalanine derivative having excellent VLA-4 inhibitory activity which is represented by the following general formula (1) or a salt thereof. (1) (In the formula, R1 represents an aromatic hydrocarbon group having 6-10 ...
|
|
WO/2005/068418A1 |
The invention encompasses novel sulfide and disulfide compounds, compositions comprising sulfide and disulfide compounds, and methods useful for treating and preventing cardiovascular diseases, dyslipidemias, dysproteinemias, and glucose...
|
|
WO/2005/066116A1 |
Compounds of the formula where the variables are as defined in the specification, are useful for preventing or treating emphysema and related pulmonary conditions of mammals and other diseases and conditions which are responsive to RAR&g...
|
|
WO/2005/066153A1 |
The present invention provides a compound of Formula (I) or a pharmaceutically acceptable salt thereof; pharmaceutical compositions comprising an effective amount of a compound of Formula I in combination with a suitable carrier, diluent...
|
|
WO/2005/066115A2 |
Compounds of the formula where the variables have the values described in the specification are antagonists of RAR&gammad retinoid receptors.
|
|
WO/2005/063705A1 |
Compounds represented by the general formula (1) or (100) have excellent inhibitory activities against cell adhesion and cell infiltration and are useful as therapeutic or preventive agents for various inflammatory and autoimmune disease...
|
|
WO/2005/063729A1 |
The present invention provides a novel compound represented by the formula (I) wherein each symbol is as defined in the specification, a salt thereof and a prodrug thereof having a superior GPR40 receptor function modulating action, whic...
|
|
WO/2005/058867A1 |
Compounds of formula (I) and salts, solvates, and physiologically functional derivatives thereof, useful for the prophylaxis or treatment of a clinical condition for which a selective β2-adrenoreceptor agonist is indicated, for example ...
|
|
WO/2005/057207A1 |
The present invention provides a method of forming an ion of formula (I) comprising the steps of: (i) reacting a compound of the formula (IIa); with a biopolymer, BP, having at least one group capable of reacting with M to form a covalen...
|
|
WO/2005/056510A2 |
The present invention relates to novel compounds corresponding to the general formula (I) below: to compounds containing them, and to their use in pharmaceutical compositions intended for use in human or veterinary medicine, or alternati...
|
|
WO/2005/053676A1 |
The use of a pentadienoic acid derivative of formula (I) for the preparation of a medicament for the prevention or treatment of hyperuricemia and/or one or several associated disorders or diseases, and/or for reducing the serum uric acid...
|
|
WO/2005/049593A2 |
Disclosed are N-acylsulfonamide compounds which inhibit the activity of anti-apoptotic protein family members, compositions containing the compounds and uses of the compounds for preparing medicaments for treating diseases during which a...
|
|
WO/2005/049594A1 |
Disclosed are N-acylsulfonamide compounds which inhibit the activity of anti-apoptotic protein family members, compositions containing the compounds and uses of the compounds for preparing medicaments for treating diseases during which o...
|
|
WO/2005/047236A1 |
The present invention relates to sulfoxide and bis-sulfoxide compounds of formula (I), formula (II), or formula (III), compositions comprising sulfoxide and bis-sulfoxide compounds, and methods useful for treating and preventing cardiova...
|
|
WO2005012220A9 |
The present invention relates to novel compounds with a variety of therapeutic uses, more particularly novel substituted cyclic alkylidene compounds that are particularly useful for selective estrogen receptor modulation. Formula (I) inc...
|
|
WO/2005/037820A1 |
The present invention relates to a process for the separation of flupentixol isomers, particularly, a process for the preparation of Z-flupentixol and the decanoate ester and novel synthetic intermediates thereof.
|
|
WO/2005/032490A2 |
The present application describes cyclic diamino compounds, derivatives thereof, and pharmaceutically acceptable salt forms thereof, which are useful as inhibitors of factor Xa.
|
|
WO/2005/028429A2 |
The application is directed to haloalkyl-substituted compounds of formula (I) wherein R7 represents haloalkyl; and R1, R2, R3, R4, R5, R6 and R8 are as defined in the claims. The compounds are inhibitors of cysteine proteases, in particu...
|
|
WO/2005/019159A1 |
A process for producing corresponding &agr -aminooxyketones in high yield and with high enantioselectivity, that is, a process for the production of optically active &agr -aminooxyketone derivatives represented by the general formula (1)...
|
|
WO/2005/017185A2 |
The present invention is directed to hepatocyte nuclear factor 4&agr (HNF-4&agr ) receptor modulator compounds. This invention is also directed to pharmaceutical compositions containing such compounds as well as methods of using such com...
|
|
WO/2005/014559A1 |
It is intended to provide novel a compound useful in drugs, in particular, in drugs for various diseases caused by infection with viruses belonging to the family Herpesviridae, i.e., in preventing or treating infections with various herp...
|
|
WO/2005/009983A1 |
The invention relates to a method for the detection of nucloephilic species with excess electronic charge, such as cyanide, sulphide or primary amines. The invention also relates to a series of compounds that are derived from pyrylium sa...
|
|
WO/2005/003125A1 |
An improved process for the preparation of key intermediates for tazarotene, 4,4 dimethyl-6-ethynylthiochroman, is provided comprising (a) reacting 4,4-dimethyl-6acetylthiochroman of the formula (I) with an acid chloride and an amido...
|
|
WO/2005/000233A2 |
The present invention is directed to compounds having the structure (I) wherein R1, R2, R3, R4, R5 and m are as defined herein. The compounds of this invention are novel therapeutic agents for the treatment of cancer, metabolic diseases ...
|
|
WO/2004/113289A2 |
A method for synthesizing Salacinol, its stereoisomers, and analogues, homologues and other derivatives thereof potentially useful as glycolsidase inhibitors. The compounds of the invention may have the general formula (I) or (II): The s...
|
|
WO/2004/111028A1 |
The invention provides cyclic onium compounds having glucosidase-inhibiting effects equivalent or superior to those of publicly known glucosidase inhibitors such as salacinol, glucosidase inhibitors characterized by containing the compou...
|
|
WO/2004/108661A1 |
The present invention is directed to compounds that are inhibitors of cysteine proteases, in particular, cathepsins B, K, L, F, and S and are therefore useful in treating diseases mediated by these proteases. The present invention is dir...
|
|
WO/2004/104051A1 |
Photoinititator systems comprising (b1) at least one aromatic aldehyde; (b2) at least one tertiary amine compound and/or a quaternary ammonium salt of a tertiary amine compound; and (b3) optionally a sensitizer compound are suitable for ...
|
|
WO/2004/093856A2 |
The present invention provides compositions and methods to treat, prevent or inhibit a neoplasia or a neoplasia-related disorder in a mammal using a combination of a COX-2 inhibitor and an alkylating-type antineoplastic agent.
|
|
WO/2004/094413A1 |
The present invention relates to compounds of formula (I): useful in treating Alzheimer’s disease and other similar diseases. These compounds include inhibitors of the beta-secretase enzyme that are useful in the treatment of Alzheimer...
|
|
WO/2004/094384A2 |
The present invention relates to compounds of formula (I) useful in treating Alzheimer's disease and other similar diseases. These compounds include inhibitors of the beta-secretase enzyme that are useful in the treatment of Alzheimer's ...
|
|
WO/2004/089529A1 |
The present invention provides a chemical compound and a method for the cleavage of labile functional groups from molecules by the interaction of electromagnetic radiation by the use of the chemical compound. Further, the invention provi...
|
|
WO/2004/087686A2 |
The subject invention concerns methods and compounds that have utility in the treatment of a condition associated with cyclooxygenase-2 mediated disorders. Compounds of particular interest are benzopyrans and their analogs defined by for...
|
|
WO/2004/078742A1 |
This invention provides new compounds, pharmaceutical compositions and diagnostic kits comprising such compounds, and methods of using such compounds for inhibiting NAALADase enzyme activity, detecting diseases where NAALADase levels are...
|
|
WO/2004/072031A2 |
Compounds of Formula (I): or pharmaceutically acceptable salts thereof, are useful in the prophylactic and therapeutic treatment of hyperglycemia and diabetes.
|
|
WO/2004/058302A1 |
The present invention provides compositions and methods to treat, prevent or inhibit a neoplasia or a neoplasia-related disorder in a mammal using a combination of a COX-2 inhibitor and a topoisomerase II inhibitor.
|
|
WO/2004/058143A2 |
A process for producing new anticancer drugs such that the drugs can be administered in a nontoxic, proto-drug form and, subsequent to a time delay which allows for differential concentration in the target cancer or invasive tissues or c...
|
|
WO/2004/056744A1 |
formulae (I)the N-oxide forms, the pharmaceutically acceptable addition salts and the stereochemically isomeric forms thereof, wherein n represents an integer being 1 or 2; R1 and R2 each independently represents hydrogen C1-4alkyl, NR9R...
|
